The global market for artificial intelligence in pharmaceuticals is forecast to reach $28.63 billion by 2034, according to a new report from Polaris Market Research. The projection reflects AI's growing role in shortening drug discovery timelines and reducing the enormous costs of bringing new therapies to market.
Cost pressure drives adoption across the value chain
Developing a single drug through clinical trials and FDA approval costs between $161 million and $2 billion, with only a small fraction of candidates succeeding. That math is pushing pharmaceutical companies toward AI-driven methods that can improve success rates and lower expenses. Algorithms now identify drug targets, analyze protein structures, and simulate chemical interactions at a scale conventional lab methods cannot match.
Natural language processing held the largest technology share in 2025, capturing 35.64% of revenue. The tools are valued for translating complex clinical and biological data into forms usable by medical experts and patients. Machine learning, deep learning, and generative AI are also gaining ground, with generative AI increasingly used to design new molecular structures and predict therapeutic potential.
Cloud services and clinical trial transformation
On deployment, cloud-based services captured the largest market share in 2025. Startups and smaller firms favor the model because it avoids heavy upfront infrastructure costs. AI is also reshaping clinical trials by improving patient recruitment through mining of electronic health records and genomic data. Predictive analytics help flag risk and refine dosing in real time.
One of the largest opportunities lies in rare and high-burden diseases that have historically been underinvested due to poor return on development costs. Alzheimer's illustrates the scale: more than 7 million Americans currently live with the disease, and unpaid caregiving in 2024 totaled nearly 19.2 billion hours, valued at over $413 billion. Without breakthroughs, the affected population could reach 13.8 million by 2050, with costs approaching $1 trillion.
Regional dynamics and remaining barriers
North America led with a 49.80% revenue share in 2025. Asia Pacific is set to post the fastest growth, driven by government-backed AI adoption initiatives in China, India, and South Korea. Barriers remain, including a shortage of skilled personnel, high implementation costs, and limited acceptance among some healthcare providers.
For pharmaceutical sales representatives and other commercial teams, understanding these shifts is increasingly part of the job. An AI Learning Path for Pharmaceutical Sales Representatives can help professionals build the fluency needed to discuss AI-driven drug development with clinicians and stakeholders.
Why this matters for healthcare professionals
The projected growth signals that AI tools will soon be embedded in drug discovery, trial design, and patient recruitment workflows that directly affect clinical practice. Healthcare professionals who understand how these systems select trial participants or flag dosing risks will be better positioned to evaluate the evidence behind new therapies and participate in research. The skills gap noted in the report is an opportunity for clinicians and pharmacists who invest early in AI literacy, particularly in areas like AI for Healthcare.
Your membership also unlocks:
